We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $508.75, moving +2.06% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.33% for the day. At the same time, the Dow added 1.08%, and the tech-heavy Nasdaq gained 0.08%.
The drugmaker's stock has dropped by 2.88% in the past month, falling short of the Medical sector's loss of 0.15% and the S&P 500's gain of 1.41%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is scheduled to release its earnings on November 2, 2026. The company's upcoming EPS is projected at $4.84, signifying a 0.83% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $3.4 billion, up 10.49% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $18.79 per share and a revenue of $13.22 billion, representing changes of +2.12% and +10.13%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.28% decrease. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 26.52. This signifies a premium in comparison to the average Forward P/E of 25.3 for its industry.
It's also important to note that VRTX currently trades at a PEG ratio of 2.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.76 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $508.75, moving +2.06% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.33% for the day. At the same time, the Dow added 1.08%, and the tech-heavy Nasdaq gained 0.08%.
The drugmaker's stock has dropped by 2.88% in the past month, falling short of the Medical sector's loss of 0.15% and the S&P 500's gain of 1.41%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is scheduled to release its earnings on November 2, 2026. The company's upcoming EPS is projected at $4.84, signifying a 0.83% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $3.4 billion, up 10.49% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $18.79 per share and a revenue of $13.22 billion, representing changes of +2.12% and +10.13%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.28% decrease. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 26.52. This signifies a premium in comparison to the average Forward P/E of 25.3 for its industry.
It's also important to note that VRTX currently trades at a PEG ratio of 2.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.76 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.